Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1281-1284

  Mowat, Eilidh ^a   Lang, Sue ^a   Williams, Craig ^b   McCulloch, Elaine ^b   Jones, Brian ^c   Ramage, Gordon ^d  

^a GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

Author keywords

A. fumigatus; Invasive aspergillosis; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; BIOFILM; CONIDIUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; FUNGAL METABOLISM; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS HYPHAE; IN VITRO STUDY; MYCELIUM; NONHUMAN; PHASE TRANSITION; SPECTROSCOPY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BIOFILMS; ECHINOCANDINS; FORMAZANS; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCELIUM; OXIDATION-REDUCTION; PYRIMIDINES; SPORES, FUNGAL; TRIAZOLES;

EID: 56649091422     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn402     Document Type: Article

References (10)

1. Denning DW, Marinus A, Cohen J et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37: 173-80.
2. Mowat E, Butcher J, Lang S et al. Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. J Med Microbiol 2007; 56 1205-12.
3. Guarro J, Llop C, Aguilar C et al. Companison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother 1997; 41: 2760-2.
4. Pujol I, Fernandez-Ballart J, Guarro J. Effect of inoculum form on in vitro antifungal susceptibilities of Aspergillus spp. J Antimicrob Chemother 2001; 47: 715-8.
5. Antachopoulos C, Meletiadis J, Sein T et al. Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J Antimicrob Chemother 2007; 59: 230-7.
6. Beauvais A, Schmidt C, Guadagnini S et al. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell Microbiol 2007; 9: 1588-600.
7. Mowat E, Williams C, Jones B et al. The characteristics of Aspergillus fumigatus mycetoma development: Is this a biofilm? Med Mycol 2008; doi:10.1080/13693780802238834.
8. Seidler MJ, Salvenmoser S, Muller FM. Aspergillus fumigatus forms biofilms with reduced antifungal drug susceptibility on bronchial epithelia cells. Antimicrob Agents Chemother 2008; doi:10.1128/ AAC.00234-08.
9. Chandra J, Kuhn DM, Mukherjee PK et al. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
10. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006; 50: 3839-46.